Why Deep Sleep Matters for Growth and Overall Health

Many people view sleep as simply a period of rest, but scientific research has revealed that deep sleep is essential for maintaining overall health. One of its most important functions is regulating the release of growth hormone, a vital hormone responsible for growth, muscle development, bone strength, and metabolic balance. Researchers have identified specific brain circuits that control the release of growth hormone during sleep. Their findings provide valuable insight into why inadequate sleep can lower growth hormone levels and increase the risk of various health conditions. Growth hormone is primarily released during deep sleep, particularly in the early stages of non-REM sleep. This hormone plays a crucial role in repairing and building muscle tissue, strengthening bones, and regulating how the body processes sugars and fats. In children and adolescents, it is especially important for healthy growth and development. The study also found that specialized nerve cells within the hypothalamus help regulate growth hormone secretion. Interestingly, researchers discovered a two-way relationship between sleep and growth hormone. While deep sleep stimulates hormone production, the hormone itself can influence areas of the brain responsible for wakefulness and alertness. These findings highlight the delicate balance between sleep quality and hormonal health. Insufficient sleep can reduce growth hormone production, while disruptions in hormone levels may negatively affect sleep quality and daytime performance.

Return to top

                       Fish Oil May Support Better Blood Sugar Control in Type 2 Diabetes

 Fish oil, a rich source of omega-3 fatty acids, may offer promising benefits for improving insulin sensitivity and blood sugar regulation, according to a recent study conducted in Brazil. Researchers found that omega-3 supplementation reduced insulin resistance and enhanced glucose tolerance in rats with a non-obese form of type 2 diabetes. It occurs when the body's cells become less responsive to insulin, leading to elevated blood sugar levels. Although obesity is a major risk factor, approximately 10–20% of individuals with type 2 diabetes are not overweight. Scientists believe that chronic inflammation may play a significant role in the development of diabetes in these cases. In the study, diabetic rats received fish oil supplements for eight weeks. At the end of the treatment period, the animals demonstrated improved blood sugar control, reduced insulin resistance, lower cholesterol and triglyceride levels, and fewer signs of inflammation. Researchers also observed that fish oil influenced the activity of immune cells known as lymphocytes. These cells shifted from a pro-inflammatory state to an anti-inflammatory state, helping to reduce inflammation throughout the body. Since persistent inflammation can impair insulin function, reducing inflammation may enhance the body's ability to regulate blood glucose effectively. The findings suggest that omega-3 fatty acids may contribute to diabetes management not only by improving lipid profiles but also by positively affecting the immune system. Recent studies in humans have also reported improvements in insulin sensitivity among individuals taking omega-3 supplements, although the overall evidence remains inconclusive.

SOURCE: Science Daily News, June 2026

Return to top

                              Understanding and Managing Metformin-Related Gastrointestinal Intolerance

Metformin remains the cornerstone and first-line therapy for type 2 diabetes. However, gastrointestinal (GI) side effects including nausea, bloating, abdominal discomfort, diarrhea, and reduced appetite can limit its tolerability and affect patient adherence. The severity and occurrence of these symptoms vary widely among individuals and may interfere with treatment initiation, dose escalation, and long-term continuation. Current evidence suggests that metformin-associated GI intolerance results from a combination of treatment-related factors and patient-specific characteristics. Treatment-related factors include the total daily dose, individual dose size, speed of dose escalation, formulation type, timing of administration with meals, kidney function, and the use of concurrent medications. Patient-related factors may include gastrointestinal sensitivity, variations in gut microbiota, alterations in bile acid metabolism, underlying medical conditions, polypharmacy, and overall treatment complexity. Importantly, the development of GI symptoms should not automatically result in permanent discontinuation of metformin. Effective management begins with identifying and addressing potentially reversible causes. Symptoms commonly arise following treatment initiation, rapid dose increases, formulation changes, or the addition of other medications. Several practical strategies can improve tolerability while allowing patients to continue benefiting from metformin therapy. These include starting with a low dose, gradually increasing the dosage, taking the medication with meals, and considering extended-release or modified-release formulations when standard preparations are not well tolerated. If GI symptoms occur, reducing the dose, slowing the titration schedule, or decreasing single-dose exposure may be more appropriate than immediately stopping treatment. For some patients, switching from an immediate-release to an extended-release formulation may lessen symptom severity, although individual responses vary and should be reassessed over time. A thorough review of concomitant medications is also important, as certain drugs may independently cause GI symptoms, affect metformin metabolism, or increase treatment complexity. When symptoms persist despite optimizing treatment-related factors, clinicians should evaluate patient-specific contributors such as pre-existing functional gastrointestinal disorders, gastroesophageal reflux disease, chronic diarrhea, multiple comorbidities, and polypharmacy. In some cases, maintaining the lowest tolerated dose of metformin as part of a broader glucose-lowering regimen may be more practical than striving for maximum dose escalation. Complete discontinuation should generally be reserved for patients whose symptoms remain persistent, clinically significant, and treatment-limiting despite appropriate adjustments.

Return to top

   Neurogenic Pelvic Floor Dysfunction in Neurological Disorders

Neurological disorders can disrupt bladder and pelvic floor control, causing neurogenic pelvic floor dysfunction (PFD) and lower urinary tract symptoms (LUTS). These problems can reduce quality of life and lead to long-term complications. Normal bladder function depends on communication between the brain, spinal cord, and peripheral nerves. When this system is damaged, symptoms such as urgency, frequency, nocturia, incontinence, and voiding difficulty may occur. Multiple Sclerosis (MS), Parkinson’s Disease (PD), and stroke are common causes of neurogenic PFD. In MS, demyelination often affects bladder and sphincter control, leading to urinary, bowel, and sexual dysfunction. In PD, impaired dopaminergic control causes urgency, frequency, nocturia, and sometimes voiding problems. After stroke, bladder dysfunction and urge incontinence are also common and may persist during recovery. Treatment is usually conservative and multidisciplinary. Pelvic Floor Muscle Training (PFMT) is the main first-line therapy and can improve symptoms and quality of life. Other options include electrical stimulation, biofeedback, and posterior tibial nerve stimulation. Although these treatments are helpful, more research is needed to develop better long-term management strategies for neurogenic PFD.

Return to top